What is Trevi Therapeutics Inc (TRVI) stock price today?

Trevi Therapeutics Inc (TRVI) currently trades at $13.82 per share. The stock has a market capitalization of $1.96B and a P/E ratio of —x.

Is TRVI stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Trevi Therapeutics Inc has a Smart Value Score of 23/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 1.29.

Is Trevi Therapeutics Inc financially healthy?

Trevi Therapeutics Inc's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 1.29 places it in the distress.

TRVI

Trevi Therapeutics Inc

NASDAQ: TRVI · HEALTHCARE · BIOTECHNOLOGY

$13.82

-0.14% today

Updated 2026-04-29

Market cap

$1.96B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.32

Dividend yield

—

52W range

$5 – $16

Volume

1.5M

Market cap

$1.96B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.32

Dividend yield

—

52W range

$5 – $16

Volume

1.5M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.0

Quality

B+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

1.3

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$21.91

+58.54%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z 1.29 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-21.11M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-29.15M	$-29.07M	$-47.91M	$-42.76M	$-8.32M
EPS	—	—	—	—	$-0.32
Free cash flow	$-28.33M	$-31.85M	$-38.29M	$-42.10M	$-21.11M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TRVI	$1.96B	23	4.3	3.0	5.0	7.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Trevi Therapeutics Inc trades at $13.82. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 1.29, it sits in the distress.

Frequently asked questions

What is Trevi Therapeutics Inc's stock price?

Trevi Therapeutics Inc (TRVI) trades at $13.82.

Is Trevi Therapeutics Inc overvalued?

Smart Value Score 23/100 (Grade F, Strong Sell).

What is the price target of Trevi Therapeutics Inc (TRVI)?

The analyst target price is $21.91, representing +58.5% upside from the current price of $13.82.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

1.29 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.trevitherapeutics.com

Quick metrics

P/S ratio—

ROE-30.20%

Beta1.00

50D MA$12.39

200D MA$10.61

Shares out0.14B

Float0.11B

Short ratio—

Avg volume1.5M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TRVI vs LLY →TRVI vs JNJ →TRVI vs ABBV →Stock screener →